Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Filgrastim

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Filgrastim. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2010-020772-38 Sponsor Protocol Number: IRST 174.05 Start Date*: 2010-09-13
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Br...
    Medical condition: Patients with primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001641-33 Sponsor Protocol Number: PETAL-Studie Start Date*: 2007-07-25
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas)
    Medical condition: Aggressive non-Hodgkin's lymphomas (first line therapy)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000563-25 Sponsor Protocol Number: 2011/119/HP Start Date*: 2012-07-27
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomized phase III study of gemcitabine and cisplatin (GC) versus high dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with...
    Medical condition: locally advanced transitional cell cancer of the bladder
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004540-29 Sponsor Protocol Number: Pona-CELL Start Date*: 2020-10-06
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia
    Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-002654-95 Sponsor Protocol Number: NET-MS Start Date*: 2023-04-17
    Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS
    Full Title: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000971-15 Sponsor Protocol Number: PLERIFLAG Start Date*: 2011-09-23
    Sponsor Name:PETHEMA
    Full Title: Multicentric, prospective, open-label, of one group and phase I-II clinical trial to analyze induction treatment with a combination of fludarabine, idarubicin, cytarabine, G-CSF and plerixafor for ...
    Medical condition: Relapsed or resistant acute myeloid leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001549-42 Sponsor Protocol Number: STH19379 Start Date*: 2020-03-27
    Sponsor Name:Sheffield Teaching Hospitals
    Full Title: A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.
    Medical condition: Highly active relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004718-32 Sponsor Protocol Number: NL72607.041.20 Start Date*: 2020-10-09
    Sponsor Name:UMC Utrecht
    Full Title: Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized co...
    Medical condition: Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003337-40 Sponsor Protocol Number: final version 2.0 Start Date*: 2006-02-13
    Sponsor Name:European Group for Blood and Marrow Transplantation (EMBT)
    Full Title: Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial)
    Medical condition: Patients with Crohn's disease who have not responded to immunosupressant medication
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012950-19 Sponsor Protocol Number: GMALL-B-ALL/NHL 2002, NILG 2009 Start Date*: 2009-10-30
    Sponsor Name:NILG (Northern Italy Leukemia Group)
    Full Title: Multicentre study to optimize therapy of B-ALL and high grade non-Hodgkin Lymphoma in Adults
    Medical condition: Burkitt`s Lymphoma Burkitt`s Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004885-18 Sponsor Protocol Number: 1805/2004 Start Date*: 2004-12-30
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Evaluation of febrile event during emopoietic progenitor cells aferesi post chemotherapy treatment in patients affected by multiple myeloma.
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028228 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021885-31 Sponsor Protocol Number: N10TIL Start Date*: 2011-03-24
    Sponsor Name:NKI-AVL
    Full Title: Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’
    Medical condition: Patients with metastatic (stage IV) melanoma will be randomized to either treatment arm A (dacarbazine) or treatment arm B (TIL) after metastasectomy and feasibility of culturing of TIL.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004398-41 Sponsor Protocol Number: IJB-BC-TDM1BM-2016 Start Date*: 2018-01-26
    Sponsor Name:Institut Jules Bordet
    Full Title: Multicentre, non-randomised, open-label, single agent phase II study to determine the clinical benefit of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer patients with brain...
    Medical condition: Metastatic HER2-positive breast cancer with brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003599-39 Sponsor Protocol Number: AMD3100-3102-DE Start Date*: 2005-12-02
    Sponsor Name:AnorMED Corp.
    Full Title: A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal ...
    Medical condition: Mobilization of stem cells prior to autologous stem cell transplantation in patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001772-38 Sponsor Protocol Number: G112 Start Date*: 2013-06-29
    Sponsor Name:A.N.M.C.O.-Fondazione Italiana lotta Malattie Cardiovasc
    Full Title: STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial
    Medical condition: Patients with left ventricular systolic disfunction after revascularization for acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000664-16 Sponsor Protocol Number: FLATauto Start Date*: 2008-02-26
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly patients w...
    Medical condition: elderly patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024291 Leukaemias acute myeloid HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006390-37 Sponsor Protocol Number: VX21-CTX001-161 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Depend...
    Medical condition: Transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10054660 Thalassemia beta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002288-84 Sponsor Protocol Number: RR3 Start Date*: 2019-08-12
    Sponsor Name:RenovoRx, Inc.
    Full Title: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable L...
    Medical condition: Locally advanced pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001308-31 Sponsor Protocol Number: PALG-AML1/2016 Start Date*: 2017-06-27
    Sponsor Name:Polish Adult Leukaemia Group (PALG)
    Full Title: A Polish Adult Leukemia Group (PALG) prospective, multicenter clinical trial to compare the efficacy of two standard induction therapies (DA-90 vs DAC) and two standard salvage regimens (FLAG-IDA ...
    Medical condition: The study will include newly diagnosed AML patients (other than acute promyelocytic leukemia); age 18-60 years, who are eligible for standard induction chemotherapy. The patients will be randomized...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005923-42 Sponsor Protocol Number: TACL2008-002/ITCC033 Start Date*: 2013-04-09
    Sponsor Name:TACL
    Full Title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC
    Medical condition: relapsed T-ALL, T-NHL
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024338 Leukemia lymphoblastic acute LLT
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) AT (Prematurely Ended) GB (Completed) IT (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 04:38:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA